Proteon Therapeutics Garners $45,000,000 Series D Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4ad50f49-9046-4fdf-9f9a-d3a9f88e7498 - Date
5/16/2014 - Company Name
Proteon Therapeutics - Mailing Address
200 West Street Waltham, MA 02451 USA - Company Description
Proteon Therapeutics is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring. - Website
http://www.proteontherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$45,000,000 - Transaction Round
Series D - Proceeds Purposes
Proceeds will be used to fully fund the first Phase 3 clinical study of PRT-201. Proteon’s lead product, PRT-201, is a recombinant human elastase in development to prolong the patency and reduce the failure of hemodialysis vascular access in patients with chronic kidney disease (CKD). - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
